A carregar cotações...

Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Valeo achieves record free cash flow in 2025 despite headwinds in the automotive sector

Valeo reports 2025 revenue of €20.9bn (+0.5% like‑for‑like) and an operating margin of 4.7%. Free cash flow after net finance costs rose to a record €371m (+50%); adjusted EBITDA margin was 14.7% and net income attributable to shareholders was €200m. Order intake amounted to €24.6bn, with strong momentum in China, while net debt fell to €4.0bn. For 2026 Valeo expects revenue of €20–21bn, an operating margin of 4.7–5.3% and free cash flow after net finance costs of over €400m; risks remain market volatility, challenges in China and high tax burdens. » Mais em de.investing.com
Valeo unveils strategy plan Elevate 2028 and confirms 2025 guidance

Valeo presented the strategy plan “Elevate 2028”, targeting €22–24 billion in revenue by 2028, an operating margin of 6–7% and free cash flow after interest of at least €500 million. The company aims to reduce its leverage to below 1.0x adjusted EBITDA and pursue an investment‑grade rating by 2028. For 2025 Valeo confirmed revenue, adjusted-EBITDA and margin targets and raised its pre-interest free cash flow forecast to slightly above €550 million; CEO Christophe Perillat cited three growth levers and a focus on electrified, safe and software-defined vehicles as well as expansion in China, India and North America. » Mais em de.investing.com
Valeo warns at IAA of cheap Chinese imports and calls for EU countermeasures

Valeo CEO Christophe Perillat warned at the IAA that automotive equipment produced in China can be up to 30 percent cheaper and that cheap Chinese imports could undermine competitiveness and jobs in Europe. Valeo stresses that it produces locally but is calling on the European Commission for support and for minimum shares of European content in vehicles sold in the EU to secure production in Europe. The company notes that the declining share of European parts further burdens the industry, since the shift to electric vehicles has already reduced jobs. » Mais em de.investing.com

Dados financeiros da empresa

No último ano, VALEO PHARMA INC.CL.A registou receitas de € 36,72 mi e um ganho líquido de -€ 18,94 mi

(EUR)	2023	YoY
Receitas	36,72 mi	78,15%
Ganho bruto	8,91 mi	90,89%
Ganho líquido	-18,94 mi	0,97%
EBITDA	-7,76 mi	35,12%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 8,76 mil
Número de ações	98,66 mi
Máximo/mínimo de 52 semanas	€ 0,10 - € 0,0000888
Dividendos	Não
Beta	0,81
PER (PE Ratio)	0,00
PEG (PEG Ratio)	0,00
P/VC (PB Ratio)	0,00
P/V (PS Ratio)	0,00

Perfil da empresa

Valeo Pharma Inc. ist ein Spezialpharmaunternehmen, das sich mit dem Erwerb, der Einlizenzierung von Marken und dem Verkauf von pharmazeutischen Produkten befasst, wobei der Schwerpunkt auf Atemwegs-, Spezial- und Krankenhausgenerika in Kanada liegt. Das Produktportfolio umfasst Enerzair Breezhaler, ein LABA/LAMA/ICS-Asthmapräparat in fester Dreifachdosis; Atectura Breezhaler, ein LABA/ICS-Asthmapräparat in Zweifachkombination; Redesca, zur Behandlung und Vorbeugung von tiefen Venenthrombosen und Lungenembolien; Onstryv zur Behandlung der idiopathischen Parkinson-Krankheit als Zusatztherapie für Patienten, die eine stabile Dosis Levodopa allein oder in Kombination mit anderen Arzneimitteln erhalten; M-Eslon, Morphinsulfat mit verlängerter Wirkstofffreisetzung zur Schmerzbehandlung; und Yondelis, ein Mittel gegen Weichteilsarkome. Darüber hinaus bietet das Unternehmen Hesperco, ein Bioflavonoid-Antioxidans zur Unterstützung des Immunsystems, Ametop für die Hautanästhesie vor einer Venenpunktion oder Venenkanüle, Benztropin, ein VPI-Anticholinergikum zur Behandlung von Parkinson, Ethacrynat-Natrium, ein Schleifendiuretikum zur Behandlung von Bluthochdruck und damit verbundenen Schwellungen, und Amikacin, ein injizierbares Antibiotikum. Das Unternehmen wurde 2003 gegründet und hat seinen Hauptsitz in Kirkland, Kanada.